Scholarlink

<p>Neoadjuvant therapy is a cornerstone of modern oncology, yet its efficacy is traditionally assessed only after treatment completion, creating a&#xa0;“black box” period where patients may receive ineffective, toxic therapies. This review explores the transformative potential of circulating tumor DNA (ctDNA) as a dynamic biomarker to overcome this limitation. The short half-life of ctDNA allows for real-time, non-invasive monitoring of tumor burden through serial liquid biopsies. A substantial body of evidence across breast, lung, colorectal, and other solid tumors demonstrates that on-treatment ctDNA dynamics are a powerful predictor of pathological response and long-term survival. Rapid ctDNA clearance is strongly associated with favorable outcomes, providing a rationale for treatment de-escalation, while persistent ctDNA identifies non-responders who may benefit from therapy intensification. Despite its promise, the clinical adoption of ctDNA is hindered by challenges including a lack of assay standardization, the existence of low-shedding tumors, and biological confounders like clonal hematopoiesis. The future of precision neoadjuvant care lies in integrating ctDNA with imaging and other biological data within a multimodal framework, leveraging artificial intelligence to guide personalized, response-adapted treatment strategies. This paradigm shift from static to dynamic assessment promises to unlock the full potential of neoadjuvant therapy, maximizing efficacy while minimizing toxicity for individual patients.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月30日

查看全文
  • Hani Moslem Ahmed,
  • Ali Fawzi Al-Hussainy,
  • Wael Waleed Mustafa,
  • S. Renuka Jyothi,
  • Priya Priyadarshini Nayak,
  • J. Bethanney Janney,
  • Gurjant Singh,
  • Aashna Sinha,
  • Hayder Naji Sameer,
  • Rasim M. Salih,
  • Mohaned Adil,
  • Pouria Salajegheh

摘要

Neoadjuvant therapy is a cornerstone of modern oncology, yet its efficacy is traditionally assessed only after treatment completion, creating a “black box” period where patients may receive ineffective, toxic therapies. This review explores the transformative potential of circulating tumor DNA (ctDNA) as a dynamic biomarker to overcome this limitation. The short half-life of ctDNA allows for real-time, non-invasive monitoring of tumor burden through serial liquid biopsies. A substantial body of evidence across breast, lung, colorectal, and other solid tumors demonstrates that on-treatment ctDNA dynamics are a powerful predictor of pathological response and long-term survival. Rapid ctDNA clearance is strongly associated with favorable outcomes, providing a rationale for treatment de-escalation, while persistent ctDNA identifies non-responders who may benefit from therapy intensification. Despite its promise, the clinical adoption of ctDNA is hindered by challenges including a lack of assay standardization, the existence of low-shedding tumors, and biological confounders like clonal hematopoiesis. The future of precision neoadjuvant care lies in integrating ctDNA with imaging and other biological data within a multimodal framework, leveraging artificial intelligence to guide personalized, response-adapted treatment strategies. This paradigm shift from static to dynamic assessment promises to unlock the full potential of neoadjuvant therapy, maximizing efficacy while minimizing toxicity for individual patients.

Graphical Abstract